Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of Dodecylamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 9/20 | 1.00 |
| ▸ | TSHR | P16473 | 3/20 | 0.93 |
| ▸ | MEN1 | O00255 | 1/20 | 0.93 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.93 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.93 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.93 |
| ▸ | CA12 | O43570 | 2/20 | 0.57 |
| ▸ | CA1 | P00915 | 2/20 | 0.57 |
| ▸ | CA2 | P00918 | 2/20 | 0.57 |
| ▸ | CA3 | P07451 | 2/20 | 0.57 |
| ▸ | CA4 | P22748 | 2/20 | 0.57 |
| ▸ | CA6 | P23280 | 2/20 | 0.57 |
| ▸ | CA5A | P35218 | 2/20 | 0.57 |
| ▸ | CA7 | P43166 | 2/20 | 0.57 |
| ▸ | CA9 | Q16790 | 2/20 | 0.57 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.57 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.57 |
| ▸ | THRB | P10828 | 1/20 | 0.57 |
| ▸ | LMNA | P02545 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromide SCHEMBL2444301 | 1.00 | DNM1 (1.00) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Bromide SCHEMBL3895282 | 1.00 | — | — | |
| Bromide SCHEMBL580087 | 1.00 | DNM1 (1.00) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Pentadecylamine SCHEMBL3049228 | 1.00 | DNM1 (1.00) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Bromide SCHEMBL1257604 | 1.00 | DNM1 (1.00) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Hexadecylamine SCHEMBL126964 | 1.00 | DNM1 (1.00) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Bromide SCHEMBL3106064 | 1.00 | DNM1 (1.00) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Bromide SCHEMBL5557202 | 1.00 | — | — | |
| Bromide SCHEMBL11380806 | 1.00 | DNM1 (1.00) | DNM1TSHRMEN1KMT2AALDH1A1 | |
| Icosylamine SCHEMBL609205 | 1.00 | DNM1 (1.00) | DNM1TSHRMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1811 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260055056-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | WILLIAM M YARBROUGH FOUND (US) | 2026-02-26 | — | — | US | claimed |
| EP-4646506-A1 | SHAPE-CONTROLLED SYNTHESIS OF III-V COLLOIDAL NANOCRYSTALS | Quantum Science Ltd (GB) | 2025-11-12 | — | — | EP | claimed |
| CN-111718716-B | Nanostructure with inorganic ligands for electroluminescent devices | 昭荣化学工业株式会社 | 2025-06-10 | — | — | CN | claimed |
| US-12310939-B2 | Method for treating rheumatoid arthritis | THE WILLIAM YARBROUGH FOUNDATION (US) | 2025-05-27 | — | — | US | claimed |
| US-20250161258-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | THE WILLIAM M YARBROUGH FOUND (US) | 2025-05-22 | — | — | US | claimed |
| WO-2025082611-A1 | COLLOIDAL ION-CAPPED PB CHALCOGENIDE NANOCRYSTALS FOR X-RAY APPLICATIONS | QDI SYSTEMS B.V (NL) | 2025-04-24 | — | — | WO | claimed |
| WO-2025082614-A1 | COLLOIDAL ION-CAPPED PB CHALCOGENIDE NANOCRYSTALS FOR SWIR APPLICATIONS | QDI SYSTEMS B.V (NL) | 2025-04-24 | — | — | WO | claimed |
| CN-119799314-A | Application of organic strong acid ligand in regulating and controlling perovskite nanocrystalline halogen activity | 浙江大学 | 2025-04-11 | — | — | CN | claimed |
| CN-119780176-A | MXene non-enzymatic uric acid electrochemical sensor based on quaternary ammonium salt modification, method and application | 浙江大学 | 2025-04-08 | — | — | CN | claimed |
| CN-119709192-A | Ytterbium-doped perovskite quantum dot and preparation method thereof | 极电光能有限公司 | 2025-03-28 | — | — | CN | claimed |
| US-20130255954-A1 | NOVEL AQUEOUS FRACTURING FLUID COMPOSITION AND FRACTURING PROCESS USING THE COMPOSITION | S.P.C.M. SA (FR) | 2013-10-03 | — | — | US | claimed |
| US-7423002-B2 | Method of neutralizing a stain on a surface | S.C. JOHNSON & SON, INC. (US) | 2008-09-09 | — | — | US | claimed |
| US-6953773-B2 | Mixtures of imidazoline quaternary ammonium and alkyl quaternary ammonium compounds | CRODA, INC. (US) | 2005-10-11 | — | — | US | claimed |
| US-6838419-B2 | Mixtures of quaternary compounds | CRODA, INC. (US) | 2005-01-04 | — | — | US | claimed |
| US-20040167057-A1 | Mixtures of quaternary compounds | CRODA, INC. | 2004-08-26 | — | — | US | claimed |
| EP-1180242-A1 | VESICLE CONTAINING POLYMERS AND SENSOR DETECTION METHODS BASED THEREON | Zeptosens AG (CH) | 2002-02-20 | — | — | EP | claimed |
| US-6283336-B1 | Article for the delivery of foam products | THE PROCTER & GAMBLE COMPANY | 2001-09-04 | — | — | US | claimed |
| WO-2000073798-A1 | VESICLE CONTAINING POLYMERS AND SENSOR DETECTION METHODS BASED THEREON | ZEPTOSENS AG (CH) | 2000-12-07 | — | — | WO | claimed |
| US-5352434-A | Barium salt and carriers in opaque polymer coating for gastrointestinal tract | STERLING WINTHROP INC. (US) | 1994-10-04 | — | — | US | claimed |
| US-5342605-A | For x-ray examination of intestinal tract; forming thin film on mucosal lining; barrier | STERLING WINTHROP INC. (US) | 1994-08-30 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260055056-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | ALK, C9, MSR1 | DNM1 4860/4885TSHR 1094/4885MEN1 4807/4885 |
| US-12310939-B2 | Method for treating rheumatoid arthritis | MIF, TNF, MMP12 | DNM1 3267/4885TSHR 1301/4885MEN1 1754/4885 |
| US-20250161258-A1 | ISOTHIOCYANATE FUNCTIONAL SURFACTANTS, FORMULATIONS INCORPORATING THE SAME, AND ASSOCIATED METHODS OF USE | TST, TMSB10, NHERF1 | DNM1 3740/4885TSHR 4015/4885MEN1 4439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.